Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia

Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia - Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039350

Enrollment

Registered

2020-03-01

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary biliary cholangitis

Interventions

pemafibrate for 12 months bezafibrate for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: UDCA-resistant PBC patients with dyslipidemia

Exclusion criteria

Exclusion criteria: Exclude patients who meet the following criteria 1) Patients who have already taken pemafibrate 2) Preexisting disorders of being allergic to pemafibrate 3) Pregnant women or breast-feeding women 4) Patients who have already taken statins. 5) Patients by whom principal investigator has determined to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Serum ALP, GGT, AST, ALT, T-Bil, T-chol, HDL-chol, TG levels in 12 months.	—

Countries

Japan

Contacts

Public ContactYuki Yamashita

Shinshu University Hospital Department of gastroenterology

ninai@shinshu-u.ac.jp0263-37-2634

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026